Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Surveillance by ultrasonography for hepatocellular carcinoma (HCC) for individuals with cirrhosis is recommended. There is debate regarding the effectiveness of surveillance in reducing mortality, and there is little information on the harms available to patients considering surveillance. The aim of this study was to provide estimates of both the benefit and harms of surveillance. A Markov model was built to simulate outcomes of individuals aged 50 years with well‐compensated cirrhosis entering surveillance. Following identification of a focal lesion by ultrasound surveillance, further investigations were defined by the European Association for the Study of the Liver/European Organization for Research and Treatment of Cancer recall policy. Benefit and harm outcomes are expressed per 1,000 patients over 5 years. For every 1,000 patients in surveillance over 5 years, there are 13 fewer deaths (95% confidence interval [CI], 12‐14) compared with no surveillance, equating to a number needed to screen to prevent one death from HCC of 77. In comparison, many more individuals experienced harm through surveillance. For every 1,000 patients, 150 (95% CI, 146‐154) had one or more false‐positive tests equating to a number needed to harm from surveillance of 7. As a consequence of a false‐positive test, 65 individuals required at least one additional unnecessary computed tomography scan or magnetic resonance imaging and 39 required an unnecessary liver biopsy according to the recall policy. Surveillance benefits were sensitive to the incidence of HCC and the mortality benefit achieved by treatment. Harms were sensitive to the rates of false‐positive testing and the frequency of liver biopsy.Conclusion: There is a balance between the small absolute mortality benefit to surveillance for HCC and the numerically more frequent harms resulting from false‐positive testing. Implementation of the recently revised American Association for the Study of Liver Diseases recommendations is predicted to reduce harms from unnecessary liver biopsy. (H epatology 2017;66:1546–1555).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Singal, A. G., Pillai, A., & Tiro, J. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001624 · Cited by 817 · cited 16×
“Similarly, there are no data on harms that accompany the studies of survival benefit synthesized by Singal et al.((6)) There is, however, consistency between the proportion of patients treated with curative intent in the study used to define the rate of false-positive testing (at 58%)((14)) and those that were used to…”
BackgroundMethodResultInfluentialAtiq, O., Tiro, J., Yopp, A. C., Muffler, A., Marrero, J. A., Parikh, N. D., Murphy, C., McCallister, K., & Singal, A. G. (2017) · Hepatology · doi:10.1002/hep.28895 · Cited by 266
Farvardin, S., Patel, J., Khambaty, M., Yerokun, O. A., Mok, H., Tiro, J. A., Yopp, A. C., Parikh, N. D., Marrero, J. A., & Singal, A. G. (2017) · Hepatology · doi:10.1002/hep.28770 · Cited by 185
Cited by
Villanueva, A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1713263 · Cited by 4,508
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Singal, A. G., Zhang, E., Narasimman, M., Rich, N. E., Waljee, A. K., Hoshida, Y., Yang, J. D., Reig, M., Cabibbo, G., Nahon, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.023 · Cited by 451
Metadata
- Authors
- Taylor, E. J., Jones, R. L., Guthrie, J. A., & Rowe, I. A.
- Venue
- Hepatology
- Published
- 2017-10-11
- Volume
- 66
- Issue
- 5
- Pages
- 1546-1555
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2625029889
- Cited by
- 46
- References
- 3
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. https://app.cochat.ai/papers/10.1002/hep.29315
- The paper
- Taylor, E. J., Jones, R. L., Guthrie, J. A., & Rowe, I. A. (2017). Modeling the benefits and harms of surveillance for hepatocellular carcinoma: Information to support informed choices. Hepatology. https://doi.org/10.1002/hep.29315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.